ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,695
-0,11%
Bitcoin
64 890,01
-0,38%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Stoke Therapeutics Inc (STOK)

  7. Stoke Therapeutics Inc (STOK) Actualités

STOK Stoke Therapeutics Inc

14,8603
-0,7397 (-4,74%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Stoke Therapeutics Inc STOK NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,7397 -4,74% 14,8603 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
15,56 15,00 15,80 15,07 15,60
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/6/202422:30BWStoke Therapeutics Announces Inducement Grants Under Nasdaq..
13/6/202422:06EDGAR2Form S-3 - Registration statement under Securities Act of..
07/6/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202422:06EDGAR2Form 8-K - Current report
05/6/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202422:30BWStoke Therapeutics to Present at Upcoming Investor..
22/5/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202422:22EDGAR2Form 144 - Report of proposed sale of securities
20/5/202422:21EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:30BWStoke Therapeutics Announces Inducement Grants Under Nasdaq..
17/5/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:12EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/5/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202413:05EDGAR2Form 8-K - Current report
06/5/202413:00BWStoke Therapeutics Reports First Quarter Financial Results..
29/4/202414:00BWStoke Therapeutics Appoints Thomas Leggett as Chief..
17/4/202414:00BWStoke Therapeutics Appoints Jason Hoitt as Chief Commercial..
04/4/202422:30BWStoke Therapeutics to Present at the 23rd Annual Needham..
28/3/202404:40BWStoke Therapeutics Announces Pricing of Upsized $125 Million..
26/3/202421:07BWStoke Therapeutics Announces Proposed Public Offering
25/3/202421:01BWStoke Therapeutics Announces Landmark New Data That Support..
05/3/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:28EDGAR2Form 144 - Report of proposed sale of securities
26/2/202416:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26/2/202416:36EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202415:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:49EDGAR2Form 144 - Report of proposed sale of securities
17/1/202422:30BWStoke Therapeutics Announces Inducement Grants Under Nasdaq..
08/1/202414:09EDGAR2Form 8-K - Current report
08/1/202414:00BWStoke Therapeutics Highlights Strategic Priorities and..
04/1/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:30BWStoke Therapeutics to Present at the 42nd Annual J.P. Morgan..
02/1/202422:29EDGAR2Form 144 - Report of proposed sale of securities
14/12/202322:05EDGAR2Form 8-K - Current report
05/12/202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202322:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202322:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202322:08EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
01/12/202315:04EDGAR2Form 8-K - Current report
01/12/202315:00BWStoke Therapeutics Presents Data From Multiple Studies of..
21/11/202314:00BWStoke Therapeutics to Present Data from the Company’s Dravet..
17/11/202322:37EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
09/11/202322:28EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
07/11/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dernières Valeurs Consultées

NASDAQ
STOK
Stoke Therapeutics
AMEX
MBP
Mid Penn Bancorp
AMEX
EVJ
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés